Literature DB >> 9765450

Costimulation of naive CD8(+) lymphocytes induces CD4 expression and allows human immunodeficiency virus type 1 infection.

S G Kitchen1, Y D Korin, M D Roth, A Landay, J A Zack.   

Abstract

Human immunodeficiency virus type 1 (HIV-1) infection requires cell surface expression of CD4. Costimulation of CD8(+)/CD4(-) T lymphocytes by anti-CD3 and anti-CD28 antibodies or by allogeneic dendritic cells induced expression of CD4 and rendered these CD8 cells susceptible to HIV-1 infection. Naive CD45RA+ cells responded with greater expression of CD4 than did CD45RO+ cells. CD8(+) lymphocytes derived from fetal or newborn sources exhibited a greater tendency to express CD4, consistent with their naive states. This mechanism of infection suggests HIV-induced perturbation of the CD8 arm of the immune response and could explain the generally rapid disease progression seen in HIV-infected children.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9765450      PMCID: PMC110322     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  42 in total

Review 1.  Isoforms of the CD45 common leukocyte antigen family: markers for human T-cell differentiation.

Authors:  L T Clement
Journal:  J Clin Immunol       Date:  1992-01       Impact factor: 8.317

Review 2.  The dendritic cell system and its role in immunogenicity.

Authors:  R M Steinman
Journal:  Annu Rev Immunol       Date:  1991       Impact factor: 28.527

Review 3.  Role of the CD28 receptor in T-cell activation.

Authors:  C H June; J A Ledbetter; P S Linsley; C B Thompson
Journal:  Immunol Today       Date:  1990-06

4.  Frequent infection of peripheral blood CD8-positive T-lymphocytes with HIV-1. Edinburgh Heterosexual Transmission Study Group.

Authors:  W J Livingstone; M Moore; D Innes; J E Bell; P Simmonds
Journal:  Lancet       Date:  1996-09-07       Impact factor: 79.321

5.  Children born to women with HIV-1 infection: natural history and risk of transmission. European Collaborative Study.

Authors: 
Journal:  Lancet       Date:  1991-02-02       Impact factor: 79.321

Review 6.  Signals and signs for lymphocyte responses.

Authors:  C A Janeway; K Bottomly
Journal:  Cell       Date:  1994-01-28       Impact factor: 41.582

7.  In vitro studies of HIV-1 expression in thymocytes from infants and children.

Authors:  E F Hays; C H Uittenbogaart; J C Brewer; L W Vollger; J A Zack
Journal:  AIDS       Date:  1992-03       Impact factor: 4.177

8.  HIV-1 entry into quiescent primary lymphocytes: molecular analysis reveals a labile, latent viral structure.

Authors:  J A Zack; S J Arrigo; S R Weitsman; A S Go; A Haislip; I S Chen
Journal:  Cell       Date:  1990-04-20       Impact factor: 41.582

9.  T-cell subset alterations in HIV-infected homosexual men: NIAID Multicenter AIDS cohort study.

Authors:  J V Giorgi; R Detels
Journal:  Clin Immunol Immunopathol       Date:  1989-07

10.  Interleukin 2 induces the expression of CD45RO and the memory phenotype by CD45RA+ peripheral blood lymphocytes.

Authors:  M D Roth
Journal:  J Exp Med       Date:  1994-03-01       Impact factor: 14.307

View more
  42 in total

1.  Functional reconstitution of thymopoiesis after human immunodeficiency virus infection.

Authors:  S G Kitchen; S Killian; J V Giorgi; J A Zack
Journal:  J Virol       Date:  2000-03       Impact factor: 5.103

2.  Human CD8 T cells of the peripheral blood contain a low CD8 expressing cytotoxic/effector subpopulation.

Authors:  Axel Trautmann; Beate Rückert; Peter Schmid-Grendelmeier; Eva Niederer; Eva-B Bröcker; Kurt Blaser; Cezmi A Akdis
Journal:  Immunology       Date:  2003-03       Impact factor: 7.397

3.  Down-modulation of CD8αβ is a fundamental activity of primate lentiviral Nef proteins.

Authors:  Anke Heigele; Michael Schindler; Clement W Gnanadurai; Jolie A Leonard; Kathleen L Collins; Frank Kirchhoff
Journal:  J Virol       Date:  2011-10-19       Impact factor: 5.103

4.  Potent HIV-specific responses are enriched in a unique subset of CD8+ T cells that coexpresses CD4 on its surface.

Authors:  Andrew Zloza; Jason M Schenkel; Allan R Tenorio; Jeffrey A Martinson; Paul M Jeziorczak; Lena Al-Harthi
Journal:  Blood       Date:  2009-08-21       Impact factor: 22.113

5.  HIV-1 Nef disrupts intracellular trafficking of major histocompatibility complex class I, CD4, CD8, and CD28 by distinct pathways that share common elements.

Authors:  Jolie A Leonard; Tracy Filzen; Christoph C Carter; Malinda Schaefer; Kathleen L Collins
Journal:  J Virol       Date:  2011-05-04       Impact factor: 5.103

6.  Late-emerging strains of HIV induce T-cell homeostasis failure by promoting bystander cell death and immune exhaustion in naïve CD4 and all CD8 T-cells.

Authors:  Catherine N Kibirige; Frederick A Menendez; Hao Zhang; Tricia L Nilles; Susan Langan; Joseph B Margolick
Journal:  Med Hypotheses       Date:  2014-04-13       Impact factor: 1.538

7.  Human immunodeficiency virus Nef induces rapid internalization of the T-cell coreceptor CD8alphabeta.

Authors:  Veronique Stove; Inge Van de Walle; Evelien Naessens; Elisabeth Coene; Christophe Stove; Jean Plum; Bruno Verhasselt
Journal:  J Virol       Date:  2005-09       Impact factor: 5.103

8.  Primary cell model for activation-inducible human immunodeficiency virus.

Authors:  Bryan Burke; Helen J Brown; Matthew D Marsden; Gregory Bristol; Dimitrios N Vatakis; Jerome A Zack
Journal:  J Virol       Date:  2007-05-02       Impact factor: 5.103

9.  High levels of human immunodeficiency virus infection of CD8 lymphocytes expressing CD4 in vivo.

Authors:  Alexandra Cochrane; Stuart Imlach; Clifford Leen; Gordon Scott; Dermot Kennedy; Peter Simmonds
Journal:  J Virol       Date:  2004-09       Impact factor: 5.103

10.  Engineering antigen-specific T cells from genetically modified human hematopoietic stem cells in immunodeficient mice.

Authors:  Scott G Kitchen; Michael Bennett; Zoran Galić; Joanne Kim; Qing Xu; Alan Young; Alexis Lieberman; Aviva Joseph; Harris Goldstein; Hwee Ng; Otto Yang; Jerome A Zack
Journal:  PLoS One       Date:  2009-12-07       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.